Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Inhibiteur tyrosine kinase")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 306

  • Page / 13
Export

Selection :

  • and

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107VON BUBNOFF, N; GORANTLA, S. H. P; KANCHA, R. K et al.Leukemia. 2005, Vol 19, Num 9, pp 1670-1671, issn 0887-6924, 2 p.Article

Dual tyrosine kinase inhibitors in chronic myeloid leukemiaMARTINELLI, G; SOVERINI, S; ROSTI, G et al.Leukemia. 2005, Vol 19, Num 11, pp 1872-1879, issn 0887-6924, 8 p.Article

La leucémie myéloïde chronique et les nouveaux inhibiteurs de tyrosine kinase : une confirmationMAHON, Francois-Xavier.Hématologie (Montrouge). 2006, Vol 12, pp 43-46, issn 1264-7527, 4 p., NS2Conference Paper

Nouveaux drivers oncogéniquesOULKHOUIR, Y; MORO-SIBILOT.Revue de pneumologie clinique (Paris). 2014, Vol 70, pp 1-4, issn 0761-8417, 4 p., HS1Article

Imatinib mesylate : Uncovering a fast track to adaptive immunitySMYTH, Mark J.The New England journal of medicine. 2006, Vol 354, Num 21, pp 2282-2284, issn 0028-4793, 3 p.Article

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)HEINRICH, Michael C; MCARTHUR, Grant A; DIRNHOFER, Stephan et al.Journal of clinical oncology. 2006, Vol 24, Num 7, pp 1195-1203, issn 0732-183X, 9 p.Article

Effects of smoking on the pharmacokinetics of erlotinibHAMILTON, Marta; WOLF, Julie L; RUSK, Jason et al.Clinical cancer research. 2006, Vol 12, Num 7, pp 2166-2171, issn 1078-0432, 6 p., 1Article

Imatinib induces hypothyroidism in patients receiving levothyroxineDE GROOT, Jan Willem B; ZONNENBERG, Bernard A; PLUKKER, John T. M et al.Clinical pharmacology and therapeutics. 2005, Vol 78, Num 4, pp 433-438, issn 0009-9236, 6 p.Article

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V K1T mutationGOTLIB, Jason; BERUBE, Caroline; LICHY, Jack H et al.Blood. 2005, Vol 106, Num 8, pp 2865-2870, issn 0006-4971, 6 p.Article

Mastocytoses systémiques : leurs traitements = Systemic mastocytosis and its treatmentPRADALIER, A; MOLITOR, J. L; TEILLET, F et al.Revue française d'allergologie et d'immunologie clinique. 2005, Vol 45, Num 6, pp 456-463, issn 0335-7457, 8 p.Article

Clinical pharmacokinetics of imatinibBIN PENG; LLOYD, Peter; SCHRAN, Horst et al.Clinical pharmacokinetics. 2005, Vol 44, Num 9, pp 879-894, issn 0312-5963, 16 p.Article

Imatinib : Bilan des effets indésirables dans un service hospitalier = Imatinib : adverse effects in an hospital serviceLa Revue Prescrire. 2005, Vol 25, Num 265, issn 0247-7750, p. 668Article

Amelioration of autoimmune nephritis by imatinib in MRL/lpr miceSADANAGA, Atsushi; NAKASHIMA, Hitoshi; MASUTANI, Kohsuke et al.Arthritis and rheumatism. 2005, Vol 52, Num 12, pp 3987-3996, issn 0004-3591, 10 p.Article

Gastrointestinal stromal tumors (GISTs) : Analysis of 20 casesBÖLÜKBASI, Hakan; NAZLI, Okay; TANSUG, Tugrul et al.Hepato-gastroenterology. 2006, Vol 53, Num 69, pp 385-388, issn 0172-6390, 4 p.Article

FLT3 tyrosine kinase inhibitorsLEVIS, Mark; SMALL, Donald.International journal of hematology. 2005, Vol 82, Num 2, pp 100-107, issn 0925-5710, 8 p.Article

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinibCROSSMAN, L. C; O'HARE, T; DEININGER, M. W. N et al.Leukemia. 2005, Vol 19, Num 11, pp 1859-1862, issn 0887-6924, 4 p.Article

Imatinib mesilate inhibits melanogenesis in vitroCARIO-ANDRE, M; ARDILOUZE, L; PAIN, C et al.British journal of dermatology (1951). 2006, Vol 155, Num 2, pp 493-494, issn 0007-0963, 2 p.Article

The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutantsTOKARSKI, John S; NEWITT, John A; DIANLIN XIE et al.Cancer research (Baltimore). 2006, Vol 66, Num 11, pp 5790-5797, issn 0008-5472, 8 p.Article

Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitorCHEEMA, Asim N; HONG, Tony; KOLODGIE, Frank et al.Journal of the American College of Cardiology. 2006, Vol 47, Num 5, pp 1067-1075, issn 0735-1097, 9 p.Article

Altered bone and mineral metabolism in patients receiving imatinib mesylateBERMAN, Ellin; NICOLAIDES, Maria; MAKI, Robert G et al.The New England journal of medicine. 2006, Vol 354, Num 19, pp 2006-2013, issn 0028-4793, 8 p.Article

Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivoLEGGAS, Markos; PANETTA, John C; YANLI ZHUANG et al.Cancer research (Baltimore). 2006, Vol 66, Num 9, pp 4802-4807, issn 0008-5472, 6 p.Article

New emerging drugs in soft tissue sarcomaMILANO, Amalia; APICE, Gaetano; FERRARI, Ettore et al.Critical reviews in oncology/hematology. 2006, Vol 59, Num 1, pp 74-84, issn 1040-8428, 11 p.Article

Structure of the kinase domain of an imatinib-resistant abl mutant in complex with the aurora kinase inhibitor VX-680YOUNG, Matthew A; SHAH, Neil P; SAWYERS, Charles L et al.Cancer research (Baltimore). 2006, Vol 66, Num 2, pp 1007-1014, issn 0008-5472, 8 p.Article

A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinibZOHLNHOFER, Dietlind; HAUSLEITER, Jorg; SCHOMIG, Albert et al.Journal of the American College of Cardiology. 2005, Vol 46, Num 11, pp 1999-2003, issn 0735-1097, 5 p.Article

Type I insulin-like growth factor receptor as a therapeutic target in cancerMILLER, Bradley S; YEE, Douglas.Cancer research (Baltimore). 2005, Vol 65, Num 22, pp 10123-10127, issn 0008-5472, 5 p.Article

  • Page / 13